EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy

By sjmartinez • October 30, 2022

Kang JJ, Ko A, Kil SH, Clair JM, Shin DS, Wang MB, Srivatsan ES. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochim Biophys Acta Rev Cancer. 2022 Oct 26:188827. doi: 10.1016/j.bbcan.2022.188827. Epub ahead of print. PMID: 36309124.

Tags: Epidermal growth factor receptor, Head and neck cancer, Head and neck squamous cell carcinoma, Hematology/Oncology, immunotherapy, Monoclonal antibodies, Publications, Receptor tyrosine kinase, Small molecular inhibitors, Veterans Administration

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas[...]

Emerging Targets in Non-Small Cell Lung Cancer

Liu L, Soler J, Reckamp KL, Sankar K. Emerging Targets in Non-Small Cell Lung Cancer. Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046. PMID:[...]

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Badros AZ, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N,[...]